DotBio
Singapore
About DotBio
DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies. DotBio develops antibody therapies that target, at multiple junctions, the interplay between tumors and the tumor microenvironment to re-establish an effective immune response. Our proprietary technologies enable the rapid generation of multi-specific antibodies targeting multiple processes. The rapid testing of combinatorial ensembles of multi-specific antibody prototypes can directly identify molecules re-activating the tumor immune response with novel synergistic mechanisms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.1M
- Funding stage: Seed
- Last round: Seed (Aug 2023)
- Website: dotbiopharma.com
- Phone: +65 6906 0743
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/dotbio-116408 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.